The Effect Of AVANDIA On The Late Asthmatic Response

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 1

Conditions: Asthma

Treatments: Drug: Rosiglitazone; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00318630

104385

Details and patient eligibility

About

This study is to investigate the effects of AVANDIA on the asthmatic response.

Enrollment: 26 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mild asthmatic treated with short-acting beta agonists only, non-smoker.

Exclusion criteria

• Inability to abstain from medications other than short-acting beta agonists and paracetamol.
• Recent administration of steroids.
• Recent respiratory infection or exacerbation of asthma.

Trial design

26 participants in 2 patient groups

Subjects receiving treatment 1

Experimental group

Description:

Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet.

Treatment:

Drug: Rosiglitazone

Drug: Placebo

Subjects receiving treatment 2

Experimental group

Description:

Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days.

Treatment:

Drug: Rosiglitazone

Drug: Placebo